OSCO serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.
Merck is pleased to announce that KEYTRUDA® (pembrolizumab) has been approved by the FDA for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. · PD-L1 diagnostic testing is not required prior to […]
Read More...Taiho Oncology announced that is offering a new patient assistance program where eligible patients pay $0 per treatment plan. Patients who are reimbursed under Medicaid, a Medicare drug benefit program, Tricare, or other state or federal programs are not eligible. To determine patient eligibility, go to or call: TaihoOncologyCopay.com or phone (844) TAIHO-4U (844-824-4648).
Read More...AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LYNPARZA for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of […]
Read More...Thank you for your support of the OSCO 2020 Best of SABCS®. OSCO is postponing this event scheduled for April 4th in Oklahoma City, OK, due to public health concerns.
Your company can sponsor OSCO and the work we do by becoming a corporate member today! For more information or to sign up, contact Kathy Musson, OSCO Executive Director at [email protected] or by phone at 405-850-8334.
The Oklahoma Society of Clinical Oncology (OSCO) is Oklahoma’s only professional organization that represents all those in oncology. Our membership works to advance the sciences of hematology and oncology and its sub-specialties, and to improve services to the public by studying the socio-economic aspects of the practice of our members.
